Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-062456
Filing Date
2021-11-30
Accepted
2021-11-30 08:30:06
Documents
3
Period of Report
2021-11-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea151499-6k_nlspharma.htm 6-K 12424
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES PRECLINICAL RESULTS CONFIRMIN ea151499ex99-1_nlspharma.htm EX-99.1 18290
3 GRAPHIC ex99-1_001.jpg GRAPHIC 11004
  Complete submission text file 0001213900-21-062456.txt   46977
Mailing Address ALTER POSTPLATZ 2 STANS V8 CH-6370
Business Address ALTER POSTPLATZ 2 STANS V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 211458359
SIC: 2834 Pharmaceutical Preparations